GPT Healthcare Ltd Valuation Turns Very Attractive Amid Sector Comparisons

Valuation Metrics Signal Enhanced Price Attractiveness

GPT Healthcare’s current price-to-earnings (P/E) ratio stands at 28.95, a level that has contributed to its upgraded valuation grade from attractive to very attractive as of 30 June 2026. This P/E multiple is notably lower than several peers within the hospital sector, including KMC Speciality at 46.58 and Gujarat Kidney at 64.87, indicating a more reasonable price relative to earnings. The price-to-book value (P/BV) ratio of 4.54 further supports this view, suggesting the stock is trading at a moderate premium to its book value, yet remains more affordable than riskier or very expensive peers such as Aashka Hospitals (P/BV not specified but implied expensive) and Lotus Eye Hospital, which is classified as risky with an exorbitant P/E of 2795.95.

Enterprise value to EBITDA (EV/EBITDA) is another key metric where GPT Healthcare fares well, currently at 14.15. This multiple is below the likes of KMC Speciality (25.09) and Gujarat Kidney (36.29), reinforcing the notion that GPT Healthcare is priced attractively on an operational earnings basis. The company’s EV to EBIT ratio of 20.86 and EV to sales of 2.52 also align with a valuation that is reasonable within the hospital sector context.

Strong Returns on Capital Highlight Operational Efficiency

Beyond valuation multiples, GPT Healthcare’s operational performance remains robust. The latest return on capital employed (ROCE) is an impressive 24.98%, signalling efficient use of capital to generate earnings. Return on equity (ROE) at 15.67% further underscores the company’s ability to deliver shareholder returns. These metrics provide a solid foundation for the upgraded buy rating and mojo score of 75.0, reflecting confidence in the company’s fundamentals.

Dividend yield, while modest at 1.68%, adds a layer of income for investors, complementing the growth potential indicated by the valuation and return metrics.

Comparative Analysis with Peers and Market Benchmarks

When compared with its hospital sector peers, GPT Healthcare’s valuation stands out as very attractive. For instance, Suraksha Diagnostics and Hemant Surgical, both rated attractive, trade at higher P/E ratios of 41.6 and 31.36 respectively, with EV/EBITDA multiples also exceeding GPT Healthcare’s 14.15. Asarfi Hospital and Hannah Joseph, rated very attractive like GPT Healthcare, have slightly lower P/E ratios of 25.3 and 22.23, but GPT’s operational returns and market positioning justify its valuation premium within this peer group.

On the broader market front, GPT Healthcare’s stock price has shown mixed returns relative to the Sensex. Year-to-date, the stock has gained 6.24%, outperforming the Sensex’s decline of 8.81%. However, over the past year, GPT Healthcare has underperformed with a negative return of 11.31% compared to the Sensex’s 4.95% loss. This divergence highlights the stock’s volatility but also its potential for recovery and growth given the improved valuation and fundamentals.

Price Movement and Market Capitalisation Context

GPT Healthcare is currently classified as a micro-cap stock, with a market cap grade reflecting this status. The share price closed at ₹149.00 on 21 July 2026, down 2.45% from the previous close of ₹152.75. The 52-week price range spans from ₹114.00 to ₹184.80, indicating a considerable trading band and room for price appreciation from current levels. The intraday high and low on the news date were ₹152.50 and ₹148.30 respectively, showing some price consolidation around the current levels.

Investors should note the recent downgrade in daily price performance, which may be a short-term reaction to broader market conditions or profit-taking. However, the fundamental valuation upgrade and strong mojo grade from Hold to Buy on 30 June 2026 suggest a positive medium-term outlook.

Outlook and Investment Considerations

GPT Healthcare’s upgraded mojo grade to Buy and a score of 75.0 reflect a strong endorsement from MarketsMOJO’s analytical framework. The valuation shift to very attractive is underpinned by a favourable P/E ratio relative to peers, solid return ratios, and a reasonable price-to-book value. These factors collectively suggest that the stock is well-positioned for investors seeking exposure to the hospital sector micro-cap space with a balanced risk-reward profile.

However, investors should remain mindful of the stock’s recent price volatility and the broader market environment. The hospital sector can be sensitive to regulatory changes, healthcare demand fluctuations, and operational risks. GPT Healthcare’s current dividend yield of 1.68% offers some income cushion, but the primary investment thesis rests on capital appreciation driven by operational efficiency and valuation re-rating.

In summary, GPT Healthcare Ltd presents a compelling case for investors looking for value within the hospital sector micro-cap universe. Its valuation metrics have improved markedly, and when combined with strong returns on capital, the stock merits consideration for portfolios seeking growth with reasonable valuation discipline.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today